Spots Global Cancer Trial Database for ak105
Every month we try and update this database with for ak105 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors | NCT04172506 | Solid Tumor Lung Cancer HCC | AK105 | 18 Years - 75 Years | Akeso | |
| A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer | NCT03866993 | Lung Cancer Non... Squamous Cell L... | AK105 Paclitaxel Carboplatin Placebo | 18 Years - 75 Years | Akeso | |
| A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma | NCT04736810 | Nasopharyngeal ... | AK105 Cisplatin Gemcitabine Anlotinib hydro... | 18 Years - 75 Years | Akeso | |
| A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors | NCT04172506 | Solid Tumor Lung Cancer HCC | AK105 | 18 Years - 75 Years | Akeso | |
| A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer | NCT04203719 | Advanced Head, ... | AK105 Anlotinib | 18 Years - | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma. | NCT05033587 | MGMT-Unmethylat... | Anlotinib AK105 Radiotherapy | 18 Years - 70 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC) | NCT04172571 | Hepatocellular ... | AK105 Anlotinib Hydro... | 18 Years - 75 Years | Akeso | |
| A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma | NCT03866967 | Nasopharyngeal ... | AK105 | 18 Years - 75 Years | Akeso | |
| A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma | NCT03866967 | Nasopharyngeal ... | AK105 | 18 Years - 75 Years | Akeso | |
| A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC) | NCT04172571 | Hepatocellular ... | AK105 Anlotinib Hydro... | 18 Years - 75 Years | Akeso | |
| Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma. | NCT05033587 | MGMT-Unmethylat... | Anlotinib AK105 Radiotherapy | 18 Years - 70 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer | NCT05244993 | Breast Neoplasm... | AK105 Anlotinib hydro... Albumin Paclita... | 18 Years - 75 Years | Liaoning Tumor Hospital & Institute | |
| A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer | NCT04203719 | Advanced Head, ... | AK105 Anlotinib | 18 Years - | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer | NCT03866980 | Lung Cancer Non... | AK105 carboplatin pemetrexed placebo Anlotinib | 18 Years - 75 Years | Akeso | |
| A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer | NCT03866980 | Lung Cancer Non... | AK105 carboplatin pemetrexed placebo Anlotinib | 18 Years - 75 Years | Akeso | |
| A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor | NCT04291248 | MSI-H or dMMR A... | AK105 Anlotinib | 18 Years - | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma | NCT03722147 | Hodgkin's Lymph... | AK105 | 18 Years - | Akeso |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
